Therefore, Bcl-xL blockade does not sensitize tumors to anti-PD-1 in this experimental system but displays increased anti-tumor efficacy when used in combination with a clinical anti-neutropenic agent. The gene discussed is BCL2L1; the disease is neoplasm.